Lyu et al. identified that HLA-DPB2/HLA-DPB1 axis exerts an anticancer role by recruiting TILs cells and NK cells into the TME, and combined with immune checkpoint inhibitors may optimize the immunotherapy for breast cancer [44]. The gene discussed is HLA-DPB2; the disease is breast carcinoma.